首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido(4,5-d)pyrimidin-2-ones and 3,4-dihydropyrido(4,3-d)pyrimidin-2-ones.
【24h】

p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido(4,5-d)pyrimidin-2-ones and 3,4-dihydropyrido(4,3-d)pyrimidin-2-ones.

机译:p38 MAP激酶抑制剂。第3部分:3,4-二氢嘧啶(4,5-d)嘧啶-2-酮和3,4-二氢嘧啶(4,3-d)嘧啶-2-酮的SAR。

获取原文
获取原文并翻译 | 示例
           

摘要

p38 inhibitors based on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-one and 3,4-dihydropyrido[4,3-d]pyrimidin-2-one platforms were synthesized and preliminary SAR explored. Among the pyrimido-pyrimidones the emergence of two sub-types of analogs-C7-amino-pyrimidines such as 24 and C7-amino-piperidines such as 42-characterized with good p38 inhibition and better off-target profiles in terms of ion channel activities was significant. Representative compound 54 in the pyrido-pyrimidone class was found to be equipotent with corresponding analog in the quinazolinone series.
机译:合成了基于3,4-二氢嘧啶[4,5-d]嘧啶-2-一和3,4-二氢吡啶并[4,3-d]嘧啶-2-one平台的p38抑制剂并探索了初步的SAR。在嘧啶-嘧啶酮中,出现了两种亚型的类似物-C7-氨基-嘧啶,例如24和C7-氨基-哌啶,例如42,具有良好的p38抑制作用和离子通道活性方面更好的脱靶谱很重要。发现吡啶基-嘧啶酮类中的代表性化合物54与喹唑啉酮系列中的相应类似物等价。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号